<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>EGFR-TKI &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/egfr-tki/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 27 Nov 2023 18:44:08 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>EGFR-TKI &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Fighting Osimertinib Resistance in Lung Cancer Treatment</title>
		<link>https://bioengineer.org/fighting-osimertinib-resistance-in-lung-cancer-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 27 Nov 2023 18:43:36 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[brigatinib]]></category>
		<category><![CDATA[C797S mutation]]></category>
		<category><![CDATA[C797S/T790M mutations]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[clinical studies]]></category>
		<category><![CDATA[EGFR amplification]]></category>
		<category><![CDATA[EGFR exon 18 mutations]]></category>
		<category><![CDATA[EGFR exon 20 mutations]]></category>
		<category><![CDATA[EGFR mutations]]></category>
		<category><![CDATA[EGFR-TKI]]></category>
		<category><![CDATA[fourth generation TKI]]></category>
		<category><![CDATA[health research]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[innovations in cancer treatment]]></category>
		<category><![CDATA[lung cancer]]></category>
		<category><![CDATA[molecular treatment methods]]></category>
		<category><![CDATA[non-small cell lung cancer]]></category>
		<category><![CDATA[NSCLC]]></category>
		<category><![CDATA[ORCHARD trial]]></category>
		<category><![CDATA[osimertinib resistance]]></category>
		<category><![CDATA[osimertinib treatment]]></category>
		<category><![CDATA[PD-1]]></category>
		<category><![CDATA[PD-L1]]></category>
		<category><![CDATA[targeted cancer therapy]]></category>
		<category><![CDATA[tyrosine kinase inhibitors]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=217045</guid>

					<description><![CDATA[Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Among its types, non-small cell lung cancer (NSCLC) constitutes approximately 85%, posing significant challenges for patients and healthcare professionals, especially due to its late-stage diagnosis and complex treatment processes. However, the last decade has witnessed transformative advancements in molecular biology and drug development, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">217045</post-id>	</item>
	</channel>
</rss>
